Editorial of Special Issue "The Biological Fate of Drug Nanocarriers".

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Enteral Route Nanomedicine for Cancer Therapy.International journal of nanomedicine · 2024
   Review
2. Current research trends of nanomedicines.Acta pharmaceutica Sinica. B · 2023
   Review
3. The feasibility of oral targeted drug delivery: Gut immune to particulates?Acta pharmaceutica Sinica. B · 2023
   Review
4. The long-circulating effect of pegylated nanoparticles revisitedActa pharmaceutica Sinica. B · 2022
   Article
5. Recent Advances in the Gastrointestinal Fate of Organic and Inorganic Nanoparticles in Foods.Nanomaterials (Basel, Switzerland) · 2022
   Review
6. Nanovesicles-Mediated Drug Delivery for Oral Bioavailability Enhancement.International journal of nanomedicine · 2022
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.